Abstract
The potassium channel activator nicorandil, under evaluation for antianginal management, has been shown to decrease neutrophil respiratory burst. Since our laboratory has demonstrated that reactive oxygen species (ROS) increase tumor necrosis factor (TNF) production, we hypothesized that nicorandil might decrease TNF production from a lipopolysaccharide (LPS) challenge via reduction of respiratory burst. Macrophage viability and TNF production were determined after an 18-hr exposure to 5.0 μg/ml LPS and varying concentrations of nicorandil. Nicorandil was not toxic to macrophages below 12 m M (94 ± 3% viability versus control) and decreased ROS and TNF production. Intracellular superoxide production decreased from 164 ± 24 OD 550 to 99 ± 6 OD 550 with 10 m M nicorandil and extracellular superoxide decreased from 3108 ± 111 to 1760 ± 210 n M. Hydrogen peroxide production was also decreased by 10 m M nicorandil. TNF production in response to 5 μg/ml LPS decreased from 6.8 ± 0.6 to 2.7 ± 0.4 ng/ml with 10 m M nicorandil. Northern and slot blot analyses demonstrate that nicorandil acts at a post-transcriptional site. These data imply that nicorandil decreases macrophage TNF production from an LPS challenge, possibly through a reduction in respiratory burst. Such compounds may prove useful in the treatment of conditions thought to be associated with free radical-lymphokine interactions such as ischemia-reperfusion injury, oxygen toxicity, adult respiratory distress syndrome, and septic shock.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.